Vaginitis (Candidal)MANAGEMENT

GENITOURINARY AND REPRODUCTIVE PRESENTATIONS · 12 SECTIONS

⚲

596 items

☷ Legend

⚲

Cardiovascular Presentations71▾

Respiratory Presentations52▾

Neurological Presentations83▾

Gastrointestinal Presentations74▾

Genitourinary and Reproductive Presentations48▾

Acute Kidney Injury (ATN)Acute Kidney Injury (Post-renal)Acute Kidney Injury (Pre-renal)Amniotic Fluid Embolism Balanitis Bladder Rupture Breast Abscess Cystitis Dialysis access complications Ectopic pregnancy Epididymitis Glomerulonephritis Hematuria (gross)Hydrocele Interstitial Cystitis Mastitis Mittelschmerz Nephrolithiasis Nephrotic Syndrome Flare Nutcracker Syndrome Orchitis Ovarian Cyst Rupture Ovarian hyperstimulation syndrome Ovarian torsion Paraphimosis Pelvic Congestion Syndrome Pelvic Inflammatory Disease (PID)Peritoneal dialysis peritonitis Phimosis Priapism Prostatitis Pyelonephritis Renal laceration Renal transplant complications and rejection Ruptured ovarian cyst Testicular torsion Torsion of Appendix Testis Tubo-ovarian abscess Ureteral Rupture Urethritis Urinary Retention Urinary tract infection (uncomplicated)Urolithiasis (renal colic)Vaginal bleeding (non-pregnant)Vaginitis (Bacterial)Vaginitis (Candidal)Varicocele Vulvovaginal Hematoma

Infectious Disease Presentations148▾

Trauma Presentations89▾

Toxicologic Presentations80▾

Psychiatric Presentations26▾

Musculoskeletal and Rheumatologic Presentations96▾

Dermatology Presentations23▾

Environmental and Exposure Presentations27▾

Hematologic and Oncologic Presentations36▾

Pediatric-Specific Presentations19▾

Endocrine and Metabolic Presentations45▾

ENT and Maxillofacial Presentations27▾

Ophthalmologic Presentations19▾

Obstetric Presentations23▾

Systemic and Miscellaneous Presentations17▾

01Approach to the Critical Patient/attcp31

Immediate priorities

›Urgency assessment

›Vulvovaginal candidiasis (VVC) is rarely a life threat in isolation

›Severity classification drives management pathway

›Immunocompromised state escalates urgency

›Red flag features requiring urgent workup

›Fever and pelvic pain suggest PID or tubo-ovarian abscess

›Cervical motion tenderness requires bimanual exam and broader evaluation

›Severe vulvar edema with systemic signs suggests necrotizing infection or sepsis

›If sepsis features present, initiate resuscitation immediately

›Broad-spectrum antibiotics within 1 hour

›IV fluid resuscitation for hypotension

Monitoring and targets

›Hemodynamic monitoring when systemically unwell

›Heart rate and blood pressure

›Tachycardia as sepsis marker

›SBP < 90 mmHg triggers escalation

›Temperature

›Fever argues against isolated VVC

›Fever with pelvic tenderness mandates PID workup

›Oxygen saturation when sepsis suspected

›SpO2 target >= 94%

›Lactate if sepsis screen positive

Escalation triggers

›Consultation and escalation indications

›Gynecology consult

›PID, tubo-ovarian abscess, or ectopic pregnancy suspected

›Severe or necrotizing vulvovaginal infection

02History/hx64

Presenting symptoms

›Cardinal symptoms of VVC

›Vulvovaginal pruritus

›Most common presenting symptom

›Often severe and distressing

›Vaginal discharge character

›White, thick, curd-like or cottage cheese consistency

›Typically odorless distinguishes from bacterial vaginosis

›Vulvar burning and irritation

›External dysuria from urethral or vulvar inflammation

›Dyspareunia

›Timing relative to menstrual cycle

›Premenstrual flare common

›Onset relative to antibiotic use

Risk factors

›Predisposing exposures

›Recent antibiotic use

›Most common modifiable risk factor

›Broad-spectrum agents carry highest risk

›Hormonal factors

›Pregnancy

›High-estrogen oral contraceptives

›Hormone replacement therapy

›Uncontrolled diabetes mellitus

›Elevated glucose in vaginal secretions

›Recurrent or refractory VVC as diabetes marker

›Immunosuppression

›HIV infection especially CD4 < 200 cells/mcL

03Physical Exam/exam52

Vitals and general

›Vital sign assessment

›Temperature

›Fever argues against isolated VVC

›Fever with pelvic pain mandates PID workup

›Heart rate and blood pressure

›Tachycardia as severity or sepsis marker

›Hemodynamic instability requires escalation

›General appearance

›Severity of distress correlates with complexity

›Systemic illness features require broader evaluation

External genitalia exam

›Vulvar findings

›Erythema and edema of vulva and labia

›Marked edema and fissuring suggests severe or complicated VVC

›Satellite lesions beyond main erythema zone

›Excoriations from pruritus

›Ulcers or vesicles

›Vesicles suggest herpes simplex virus

›Ulcers require alternative diagnosis consideration

›Architectural changes

›Lichen sclerosus: white atrophic plaques

›Lichen planus: erosive or reticular pattern

Speculum and vaginal exam

›Speculum findings

›Vaginal discharge character

›White, thick, adherent curd-like discharge typical of VVC

›Thin homogenous discharge suggests bacterial vaginosis

04Differential Diagnosis/ddx54

Life threats and urgent diagnoses

›Urgent diagnoses requiring exclusion

›Pelvic inflammatory disease

›ICD-10 N73.0 acute parametritis and pelvic cellulitis

›Fever, bilateral lower abdominal pain, cervical motion tenderness

›Tubo-ovarian abscess

›ICD-10 N70.93

›Adnexal mass on exam or ultrasound

›Ectopic pregnancy

›ICD-10 O00.9

›Pelvic pain and missed period require urine hCG

›Vulvar necrotizing fasciitis (Fournier gangrene)

›ICD-10 N76.89

›Rapidly spreading erythema, crepitus, systemic toxicity

›Surgical emergency requiring immediate consultation

Infectious mimics

›Infectious vaginitis differential

›Bacterial vaginosis

›ICD-10 N76.0

›Thin, gray-white, homogenous discharge with fishy odor

›pH > 4.5 and clue cells on wet mount

›Positive whiff test with KOH application

›Trichomoniasis

›ICD-10 A59.01

›Frothy, yellow-green discharge with vulvar irritation

›pH > 4.5 and motile trichomonads on wet mount

›Strawberry cervix on speculum exam

›Herpes simplex vulvitis

05Laboratory Tests/lt48

Bedside testing

›Point-of-care microscopy

›Vaginal pH

›Normal vaginal pH 4.0 to 4.5 in VVC

›pH > 4.5 suggests bacterial vaginosis or trichomoniasis

›Use pH paper or colorimetric test strip

›Saline wet mount microscopy

›Evaluation for clue cells of bacterial vaginosis

›Evaluation for motile trichomonads

›Lactobacillus predominance in VVC

›KOH preparation (10% KOH)

›Pseudohyphae and budding yeast cells diagnostic of VVC

›Sensitivity approximately 50% compared to culture

›Specificity high when positive

›Whiff test with KOH

›Negative in VVC (no amine odor)

›Positive result fishy odor suggests bacterial vaginosis

Confirmatory and culture testing

›Vaginal yeast culture

›Gold standard for VVC diagnosis

›Allows species identification (C. albicans vs non-albicans)

›Required for recurrent or treatment-refractory disease

›Species-level identification guides therapy

›C. albicans responds to azoles in most cases

›C. glabrata often azole-resistant

›C. auris emerging resistant pathogen requiring special handling

›Sensitivity and susceptibility testing

›Indicated for non-albicans species

06Diagnostic Tests/dt55

Scoring Systems

›VVC classification systems

›Uncomplicated VVC criteria (all must be present)

›Mild to moderate severity

›Sporadic or infrequent episodes

›Presumed Candida albicans etiology

›Non-immunocompromised host

›Complicated VVC criteria (any one present)

›Severe signs including extensive vulvar erythema, edema, excoriation, or fissures

›Four or more symptomatic episodes in 12 months (RVVC)

›Non-albicans Candida species suspected or confirmed

›Pregnancy

›Uncontrolled diabetes, immunosuppression, or HIV infection

›RVVC definition per IDSA and CDC guidelines

›Four or more mycologically confirmed episodes per year

›Maintenance suppressive therapy required after induction

MRI

›MRI pelvis role in vulvovaginal disease

›Not indicated for routine VVC evaluation

›Diagnosis established by clinical and microscopic criteria

›Radiation-free alternative to CT when anatomic detail required

›Indications in complex or refractory vulvovaginal disease

›Suspected Bartholin gland abscess with deep extension

›Suspected necrotizing fasciitis extent mapping prior to surgery

›Complex pelvic pathology when ultrasound is equivocal

›MRI findings in complicated vulvar infections

›Fascial plane edema and gas in necrotizing fasciitis

›Multiloculated fluid collections in deep abscesses

07Disposition/dispo34

Outpatient criteria

›Discharge suitability for VVC

›Uncomplicated VVC without systemic features

›Hemodynamically stable without fever

›No pelvic tenderness or adnexal findings

›Diagnosis confirmed or clinically certain

›Medication adherence and access confirmed

›Topical or oral antifungal prescription dispensed

›Patient able to follow treatment course

›Adequate follow-up plan

›Return precautions clearly communicated

›Follow-up with primary care or gynecology within 1 to 4 weeks for recurrent cases

Admission indications

›Criteria for admission or escalation

›PID with failure of outpatient therapy or inability to tolerate oral antibiotics

›Temperature >= 38.3 C

›WBC > 11.0 x10(9)/L

›Tubo-ovarian abscess identified

›Requires IV antibiotics and surgical planning

›Admission mandatory

›Necrotizing vulvar infection

›Immediate surgical consultation

›ICU-level care often required

›Immunocompromised patient with systemic fungal infection concern

›Candidemia or invasive candidiasis not excluded

›Blood cultures and infectious disease consult

Follow-up planning

›Outpatient follow-up recommendations

08Treatment/t89

Uncomplicated VVC first-line therapy

›Oral azole therapy

›Fluconazole 150 mg PO single dose

›Preferred by most patients for convenience

›Clinical cure rate > 90%

›Contraindicated in pregnancy

›Drug interactions: warfarin, phenytoin, cyclosporine, QT-prolonging agents

›Efficacy equivalent to topical azoles for uncomplicated VVC

›Class I recommendation for either oral or topical route

›Patient preference guides route selection

›Topical azole therapy

›Clotrimazole 1% cream or 100 mg vaginal tablet

›7-day course for cream

›7-day course for vaginal tablet

›Miconazole 2% cream or 100 mg vaginal suppository

›7-day course for cream

›7-day course for suppository

›Available OTC in many jurisdictions

›Terconazole 0.4% or 0.8% cream

›7-day course for 0.4% cream

›3-day course for 0.8% cream

›Prescription required

›Butoconazole 2% sustained-release cream

›Single 5 g intravaginal application

›Bioadhesive formulation

›Patient counseling for topical agents

›Oil-based formulations may weaken latex condoms and diaphragms

›Complete full course even if symptoms improve early

Severe acute VVC treatment

›Extended fluconazole dosing

›Fluconazole 150 mg PO every 72 hours for 2 to 3 doses

›IDSA recommendation for severe acute VVC

›Based on severity score of extensive erythema, edema, or fissuring

›Topical azole extended course alternative

›7 to 14 days of any topical azole agent

›Preferred when fluconazole contraindicated

Recurrent VVC management

›Induction phase

›Fluconazole 150 mg PO every 72 hours for 3 doses

›Days 1, 4, and 7 of induction

›Achieves mycologic cure before maintenance phase

›Topical azole induction alternative

›10 to 14 days of topical azole therapy

›Culture to confirm clearance

›Maintenance suppressive phase

›Fluconazole 150 mg PO once weekly for 6 months

›Reduces recurrence in approximately 90% during treatment

›Recurrence risk returns after cessation

›IDSA Class I recommendation

›Monitoring during maintenance

›Hepatic function testing if prolonged course in patients with liver disease risk

›Drug interaction review at initiation

›Newer agents for RVVC

›Oteseconazole (Vivjoa)

›FDA-approved 2022 for RVVC

›Oral capsule 150 mg daily for 14 days then 150 mg once weekly for 11 weeks

›Contraindicated in women of reproductive potential due to teratogenicity

›Not suitable for premenopausal women unless effective contraception confirmed

›Ibrexafungerp (Brexafemme)

›FDA-approved for acute and recurrent VVC

›300 mg PO twice daily for 1 day for acute VVC

›300 mg PO twice daily for 1 day each month for 6 months for RVVC

›Triterpenoid glucan synthase inhibitor with novel mechanism

›Teratogenic — requires effective contraception during treatment and 4 days after

Non-albicans candidiasis treatment

›C. glabrata (Nakaseomyces glabrata) management

›Intravaginal boric acid

›600 mg gelatin capsule intravaginally once daily for 14 days

›Evidence level supports use for non-albicans or azole-refractory VVC

›Toxic if ingested orally — patient education required

›Not for use in pregnancy

›Nystatin vaginal suppositories

›100,000 units daily for 14 days

›Alternative when boric acid unavailable or refused

›Flucytosine 5-FC cream compounded intravaginal

›17% cream 5 g nightly for 14 days

›Combined with amphotericin B cream in refractory cases

›Specialist referral for persistent non-albicans VVC

›Sensitivity testing to guide therapy

›Infectious disease or gynecology input

Adjunctive measures

›Non-pharmacologic support

›Symptom relief during treatment

›External hydrocortisone 1% cream short course for severe pruritus

›Cool sitz baths for vulvar comfort

›Glycemic optimization in diabetic patients

›Target HbA1c reduction reduces recurrence

›Endocrine referral if diabetes poorly controlled

›Avoid precipitating factors

›Discontinue or modify antibiotic courses when possible

›Switch to lower-estrogen OCP or alternative contraception if hormonal trigger

›Probiotics

›No evidence supports use for VVC treatment or prevention

›IDSA does not recommend routine use

09Special Populations/sp57

Pregnancy

›VVC in pregnancy

›Prevalence increased to 30% in third trimester

›Elevated estrogen and glycogen promote Candida overgrowth

›More frequent and more severe episodes common

›Fluconazole contraindicated throughout pregnancy

›Associated with increased spontaneous abortion risk

›Craniofacial and cardiac defects in first trimester animal data

›FDA category X for fluconazole in pregnancy

›Observational human data support spontaneous miscarriage risk

›Safe treatments in pregnancy

›Topical azoles recommended for all trimesters

›Clotrimazole 1% cream or 100 mg tablet 7-day course preferred

›Miconazole 2% cream or 100 mg suppository 7-day course acceptable

›Terconazole topical alternatives

›Treatment duration in pregnancy

›7-day courses preferred over shorter courses

›Higher mycologic cure rate with longer topical therapy in pregnancy

›Oteseconazole and ibrexafungerp contraindicated in pregnancy

›Teratogenic risk in animal models

›Boric acid contraindicated in pregnancy

›Clinical implications

›Symptomatic treatment reduces maternal discomfort

›No proven reduction in preterm birth with VVC treatment

Geriatric

›VVC in older adults

›Atypical presentation

›Pruritus may be attributed to atrophic vaginitis

10Background/b57

Epidemiology

›Burden and prevalence

›Second most common cause of infectious vaginitis

›Bacterial vaginosis is most common

›Approximately 1.4 million outpatient visits annually in the United States

›Lifetime prevalence

›Approximately 75% of women experience at least one episode before menopause

›Approximately 40% to 45% experience two or more episodes

›RVVC prevalence

›Approximately 5% to 8% of women in reproductive years

›Significant impact on quality of life and healthcare utilization

›Causative organism distribution

›Candida albicans responsible for approximately 85% to 90% of cases

›Candida glabrata (Nakaseomyces glabrata) accounts for most remaining cases

›Candida parapsilosis, C. tropicalis, C. krusei less common

›Non-albicans species rising with azole use and immunosuppression

Pathophysiology

›Candida colonization and infection mechanisms

›Normal vaginal carriage

›Candida colonizes vagina asymptomatically in 10% to 20% of women

›Transition from colonization to infection involves host-pathogen interaction

›Virulence factors of C. albicans

›Hyphal formation and pseudohyphal invasion of epithelium

›Adherence proteins and biofilm formation

›Secreted aspartyl proteases damaging mucosal barrier

›Host susceptibility factors

›Elevated vaginal glycogen provides substrate for Candida growth

›Estrogen increases glycogen deposition explaining premenstrual flare and pregnancy risk

11Patient Discharge Instructions/pdi32

copy discharge instructions

›Vaginal yeast infection home care instructions

›Take all medication exactly as prescribed

›If using vaginal cream or suppository, insert as directed each night for the full course

›If given a single fluconazole tablet, take it with food or water

›Do not stop treatment early even if symptoms improve

›Managing symptoms while treatment takes effect

›Cool water rinse or sitz bath to relieve vulvar itching and burning

›Wear loose, breathable cotton underwear

›Avoid tight-fitting clothing and synthetic fabrics

›Pat the area dry gently after bathing; avoid excessive moisture

›What to avoid during treatment

›Avoid sexual activity until symptoms fully resolve and treatment is complete

›Vaginal creams can weaken latex condoms and diaphragms — use alternative contraception

›Avoid douching or scented vaginal products

›Avoid perfumed soaps, bubble baths, or hygiene sprays in the genital area

›Reducing future risk

›If symptoms developed after antibiotic use, speak to your doctor about fluconazole 150 mg at the time of future antibiotic courses

›If you have diabetes, maintaining good blood sugar control reduces yeast infection risk

›Wipe front to back after using the toilet

›Return to the emergency department if you experience

›Fever or chills

›Pelvic pain or lower abdominal pain

›Pain during intercourse or with urination that worsens

›Symptoms not improving after completing the full course of treatment

›Symptoms returning within 2 months of treatment

›Vaginal discharge that changes character (becomes frothy or develops a fishy odor)

›Rash, blistering, or ulcers on the vulva or vagina

12References/r23

Guidelines and key sources

›Primary clinical guidelines

›CDC Sexually Transmitted Infections Treatment Guidelines 2021 — VVC section

›Classification of uncomplicated vs complicated VVC

›First-line and alternative treatment regimens

›IDSA Clinical Practice Guidelines for Candidiasis (Pappas et al.)

›Covers VVC treatment including RVVC management

›Class recommendations for fluconazole maintenance therapy

›American Academy of Family Physicians (AAFP) Vaginitis Diagnosis and Treatment 2025

›Diagnostic algorithm for vaginitis evaluation

›Differential diagnosis framework

›Evidence references

›Sobel JD. Vulvovaginal candidosis. Lancet 2007 — foundational epidemiology and pathophysiology

›Pappas PG et al. Clinical Practice Guideline for the Management of Candidiasis — IDSA

›Workowski KA et al. Sexually Transmitted Infections Treatment Guidelines — CDC MMWR 2021

›Blostein F et al. Recurrent vulvovaginal candidiasis — Annals of Epidemiology 2017

›FDA approvals and drug references

›FDA approval of oteseconazole (Vivjoa) May 2022 for RVVC

›FDA approval of ibrexafungerp (Brexafemme) June 2021

›ICD-10 and coding references

›ICD-10 B37.3 — Candidiasis of vulva and vagina

›ICD-10 N76.0 — Acute vaginitis (bacterial vaginosis)

›ICD-10 A59.01 — Trichomonal vulvovaginitis

›SNOMED CT concept: vulvovaginal candidiasis disorder

Learn More: Vaginitis (Candidal)→

Comprehensive Clinical Review

Structured, evidence-informed, long-form analysis for deeper understanding.

Evidence & Review

Reviewed by SymptomDx Medical Team · Last reviewed August 18, 2026

SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.